Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Mark

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
Nature|March 28, 2014
Quantum chaos in ultracold collisions of gas-phase erbium atomsAlbert Frisch, Michael Mark, Kiyotaka Aikawa, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 5, 2014
The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty ratHenrik H Hansen, Jacob Jelsing, Carl Frederik Hansen, et al.
Diabetologia|June 8, 2014
Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptinHeike Zimdahl, Carina Ittrich, Ulrike Graefe-Mody, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|November 25, 2010
Wireless channel characterization for mm-size neural implantsMichael Mark, Toni Bjorninen, Yuhui David Chen, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|July 26, 2014
Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria dietSteven P Vickers, Sharon C Cheetham, Katie R Headland, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2016
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)Sabine Schmid, Oliver Gautschi, Sacha Rothschild, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2008
3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitorsMatthias Eckhardt, Norbert Hauel, Frank Himmelsbach, et al.
Sports Health|December 13, 2025
Real-Time Concurrent Neurophysiological Responses to Dynamic In-Motion Physical and Cognitive Functional Tasks in Division I AthletesThomas Palmer, Bob Mangine, Audrey Hill-Lindsay, et al.
Bone Reports|August 14, 2024
Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot studyMichael Mark, Alfonso Rojas Mora, Thomas Winder, et al.
Scientific Reports|January 12, 2023
Linagliptin treatment is associated with altered cobalamin (VitB12) homeostasis in mice and humansHarald Tammen, Martin Kömhoff, Denis Delić, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Nature|March 28, 2014
Quantum chaos in ultracold collisions of gas-phase erbium atomsAlbert Frisch, Michael Mark, Kiyotaka Aikawa, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 5, 2014
The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty ratHenrik H Hansen, Jacob Jelsing, Carl Frederik Hansen, et al.
Diabetologia|June 8, 2014
Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptinHeike Zimdahl, Carina Ittrich, Ulrike Graefe-Mody, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|November 25, 2010
Wireless channel characterization for mm-size neural implantsMichael Mark, Toni Bjorninen, Yuhui David Chen, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|July 26, 2014
Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria dietSteven P Vickers, Sharon C Cheetham, Katie R Headland, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2016
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)Sabine Schmid, Oliver Gautschi, Sacha Rothschild, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2008
3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitorsMatthias Eckhardt, Norbert Hauel, Frank Himmelsbach, et al.
Sports Health|December 13, 2025
Real-Time Concurrent Neurophysiological Responses to Dynamic In-Motion Physical and Cognitive Functional Tasks in Division I AthletesThomas Palmer, Bob Mangine, Audrey Hill-Lindsay, et al.
Bone Reports|August 14, 2024
Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot studyMichael Mark, Alfonso Rojas Mora, Thomas Winder, et al.
Scientific Reports|January 12, 2023
Linagliptin treatment is associated with altered cobalamin (VitB12) homeostasis in mice and humansHarald Tammen, Martin Kömhoff, Denis Delić, et al.
Pageof 9